Clinical applications of creatine supplementation on paediatrics

Current Pharmaceutical Biotechnology

Volumn 10, Issue 7, 2009, Pages 683-690

  Evangeliou, Athanasios ^a   Vasilaki, Konstantina ^a   Karagianni, Paraskevi ^b   Nikolaidis, Nikolaos ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

Acquired disorders of creatine metabolism; Brain and spinal cord injury; Creatine; Creatine deficiency syndromes; Intermediary metabolism; Mental performance; Neuroprotection

Indexed keywords

ARGININE; CREATINE; GLUTAMINE; MOCLOBEMIDE; ORNITHINE; PLACEBO; PREDNISOLONE; TACRINE; THIOCTIC ACID; UBIDECARENONE;

BRAIN INJURY; CHOROID GYRATE ATROPHY; COGNITIVE DEFECT; CREATINE DEFICIENCY SYNDROME; DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG INDICATION; DUCHENNE MUSCULAR DYSTROPHY; ENZYME MECHANISM; HUMAN; HUNTINGTON CHOREA; KEARNS SAYRE SYNDROME; MELAS SYNDROME; MENTAL PERFORMANCE; METABOLIC DISORDER; MUSCLE DISEASE; MUSCULAR DYSTROPHY; MYALGIA; NONHUMAN; OPTIMAL DRUG DOSE; PROTEIN SYNTHESIS; RETINA GYRATE ATROPHY; REVIEW; SPINAL CORD INJURY;

ANIMALS; CHILD; CREATINE; DIETARY SUPPLEMENTS; HUMANS; METABOLIC DISEASES; METABOLISM, INBORN ERRORS; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 71849112770     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920109789542075     Document Type: Review

References (72)

1. Walker, J.B. (1979) Creatine: biosynthesis, regulation, and function. Adv. Enzymol., 50, 177-242.
2. Guerrero-Ontiveros, M.L. and Wallimann, T. (1998) Creatine supplementation in health and disease. Effects of chronic creatine supplementation in vivo: downregulation of the expression of creatine transporter isoforms in skeletal muscle. Mol. Cell Biochem., 184, 427-437.
3. Snow, R.J. and Murphy, R.M. (2001) Creatine and the creatine transporter: a review. Mol. Cell Biochem., 224(1-2),169-181
4. Wyss, M. and Kaddurah-Daouk, R. (2000) Creatine and creatinine metabolism. Physiol. Rev., 80, 1107-1213.
5. Persky, A. and Brazeau, G. (2001) Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol. Rev., 53, 161-176. (Pubitemid 32476115)
6. Parise, G.; Mihic, S.; MacLennan, D.; Yarasheski, K.E. and Tarnopolsky, M.A. (2001) Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. J Appl. Physiol., 91(3), 1041-1047.
7. Sharov, V.G.; Saks, V.A.; Kupriyanov, V.V.; Lakomkin, V.L.; Kapelko, V.I.; Steinschneider, A.Ya. and Javadov, S.A. (1987) Protection of ischemic myocardium by exogenous phosphocreatine I. Morphologic and phosphorus 31-nuclear magnetic resonance studies. J. Thorac. Cardiovasc. Surg., 94(5),749-761.
8. Tarnopolsky, M.A. and Beal, M.F. (2001) Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol., 49, 561-574.
9. Butterfield, D.A. and Kanski, J. (2001) Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev., 122(9), 945-962.
10. Brewer, G. J.; Jones, T.T.; Wallimann, T. and Schlattner, U. (2004) Higher respiratory rates and improved creatine stimulation in brain mitochondria isolated with anti-oxidants. Mitochondrion, 4(1), 49-57. (Pubitemid 41123638)
11. Dolder, M.; Walzel, B.; Speer, O.; Schlattner, U. and Wallimann, T.J. (2003) Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation Biol. Chem., 278(20), 17760-17766. (Pubitemid 36799379)
12. Kaemmerer, W.F.; Rodrigues, C.M.; Steer, C.J. and Low, W.C. (2001) Creatine-supplemented diet extends Purkinje cell survival in spinocerebellar ataxia type 1 transgenic mice but does not prevent the ataxic phenotype Neuroscience, 103(3), 713-724.
13. Prass, K.; Royl, G.; Lindauer, U.; Freyer, D.; Megow, D.; Dirnagl, U.; Stöckler-Ipsiroglu, G.; Wallimann, T. and Priller, J. (2007) Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. Cereb Blood Flow Metab., 27(3), 452-459. (Pubitemid 46310421)
14. Sakellaris, G.; Kotsiou, M.; Tamiolaki, M.; Kalostos, G.; Tsapaki, E.; Spanaki, M.; Spilioti, M.; Charissis, G. and Evangeliou, A. (2006) Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration: an open label randomized pilot study J. Trauma, 61(2), 322-329. (Pubitemid 44265811)
15. Boero, J.; Qin,W.; Cheng, J.; Woolsey, T.A.; Strauss, A.W. and Khuchua, Z. (2003) Restricted neuronal expression of ubiquitous mitochondrial creatine kinase: changing patterns in development and with increased activity. Mol. Cell. Biochem., 244(1-2), 69-76.
16. Streijger, F.; Oerlemans, F.; Ellenbroek, B.A.; Jost, C.R.; Wieringa, B. and Van der Zee, C.E. (2005) Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit. Behav. Brain Res., 157(2), 219-234. (Pubitemid 40082565)
17. Klivenyi, P.; Calingasan, N.Y.; Starkov, A.; Stavrovskaya, I.G.; Kristal, B.S.; Yang, L.; Wieringa, B. and Beal, M.F. (2004) Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol. Dis., 15(3), 610-617. (Pubitemid 38429976)
18. Andres, R.H.; Ducray, A.D.; Huber, A.W.; Pérez-Bouza, A.; Krebs, S.H.; Schlattner, U.; Seiler, R.W.; Wallimann, T. and Widmer, H.R. (2005) Effects of creatine treatment on survival and differentiation of GABAergic neurons in cultured striatal tissue. J. Neurochem., 95(1), 33-45. (Pubitemid 41384423)
19. Ducray, A.D.; Qualls, R.; Schlattner, U.; Andres, R.H.; Dreher, E.; Seiler, R.W.; Wallimann, T. and Widmer, H.R. (2007) Creatine promotes the GABAergic phenotype in human fetal spinal cord cultures. Brain Res., 1137(1), 50-57 (Pubitemid 46240055)
20. Nakamura, M.; Okano, H.; Toyama, Y.; Dai, H.N.; Finn, T.P. and Bregman, B.S.J. (2005) Transplantation of embryonic spinal cordderived neurospheres support growth of supraspinal projections and functional recovery after spinal cord injury in the neonatal rat. Neurosci. Res., 81(4), 457-468.
21. Wendt, S.; Dedeoglu, A.; Speer, O.; Wallimann, T.; Beal, M.F. and Andreassen, O.A. (2002) Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. Free Radic. Biol. Med., 32(9), 920-926.
22. Hausmann, O. N.; Fouad, K.; Wallimann, T. and Schwab, M.E. (2002) Protective effects of oral creatine supplementation on spinal cord injury in rats. Spinal Cord, 40, 449-456. (Pubitemid 35001733)
23. Almeida, S.L. and Rosenberg, H.E. (2006) Are cerebral creatine deficiency syndromes on the radar screen? Future Neurol., 1(5), 637-649.
24. Matthews, R.T.; Yang, L.; Jenkins, B.G.; Ferrante, R.J.; Rosen, B.R.; Kaddurah-Daouk, R. and Beal, M.F. (1998) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci., 18, 156-163. (Pubitemid 28046777)
25. Matthews, R.T.; Ferrante, R.J.; Klivenyi, P.; Yang, L.; Klein, A.M.; Mueller, G.; Kaddurah-Daouk, R. and Beal, M.F. (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol., 157, 142-149. (Pubitemid 29226877)
26. Ferrante, R.J.; Andreassen, O.A.; Jenkins, B.G.; Dedeoglu, A.; Kuemmerle, S.; Kubilus, J.K.; Kaddurah-Daouk, R.; Hersch, S.M. and Beal, M.F. (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci., 20, 4389-4397. (Pubitemid 30396603)
27. Mazzini, L.; Balzarini, C.; Colombo, R.; Mora, G.; Pastore, I.; De Ambrogio, R. and Caligari, M. (2001) Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. J. Neurol. Sci., 191(1-2),139-144 (Pubitemid 33035907)
28. Schulze, A.; Bachert, P.; Schlemmer, H.; Harting, I.; Polster, T.; Salomons, G.; Verhoeven, N.M.; Jakobs, C.; Fowler, B.; Hoffmann, G.F. and Mayatepek, E. (2003) Lack of creatine in muscle and brain in an adult with GAMT deficiency. Ann. Neurol., 53(2), 248-251.
29. Rosenberg, E.H.; Muñoz, C.M.; Degrauw, T.J.; Jakobs, C. and Salomons, G.S. (2006) Overexpression of wild-type creatine transporter SLC6A8 restores creatine uptake in primary SLC6A8- deficient fibroblasts. J. Inherit. Metab. Dis., 29(2-3), 345-346. (Pubitemid 43880632)
30. Battini, R.; Alessandri, M.G.; Leuzzi, V.; Moro, F.; Tosetti, M.; Bianchi, M.C. and Cioni, G. (2006) Arginine:glycine amidinotrans ferase (AGAT) deficiency in a newborn: early treatment can prevent phenotypic expression of the disease. J. Pediatr., 148(6), 828-830
31. Sipilla, I.; Valle, D. and Brusilow, S. (1992) Low guanidinoacetic acid and creatine concentrations in gyrate atrophy of the choroids and retina Guanidino Compouds in Biology and Medicine. (De Deyn, P.; Marescau, B.; Stalon, V. and Qureshi, I., Eds.), Libbey: London, 379-383.
32. Vannas-Sulonen, K.; Sipila, I.; Vannas, A.; Simell, O. and Rapola, J. (1985) Gyrate atrophy of the choroid and retina. A five-year follow- up of creatine supplementation. Ophthalmology, 92(12), 1719-1727. (Pubitemid 16172077)
33. Valtonen, M.; Nanto-Salonen, K.; Jaaskelainen, S.; Heinanen, K.; Alanen, A.; Heinonen, O.J.; Lundbom, N.; Erkintalo, M. and Simell, O. (1999) Central nervous system involvement in gyrate atrophy of the choroid and retina with hyperornithinaemia. J. Inherit. Metab. Dis., 22(8), 855-866
34. Heinanen, K.; Nanto-Salonen, K.; Komu, M.; Erkintalo, M.; Alanen, A.; Heinonen, O.J.; Pulkki, K.; Nikoskelainen, E.; Sipila, I. and Simell, O. (1999) Creatine corrects muscle 31P spectrum in gyrate atrophy with hyperornithinaemia. Eur. J. Clin. Invest, 29(12), 1060-1065.
35. Nanto-Salonen, K.; Komu, M.; Lundbom, N.; Heinanen, K.; Alanen, A.; Sipila, I. and Simell, O. (1999) Reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia. Neurology, 53(2), 249-250.
36. Mahoney, D.J.; Parise, G. and Tarnopolsky, M.A. (2002) Nutritional and exercise-based therapies in the treatment of mitochondrial disease. Curr. Opin. Clin. Nutr. Metab. Care, 5, 619-629. (Pubitemid 40684628)
37. Tarnopolsky, M.A. and Raha, S. (2005) Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. Med. Sci. Sports Exerc., 37, 2086-2093.
38. Schmeidel, J.; Jackson, S.; Schafer, J. and Reichmann, H. (2003) Mitochondrial cytopathies. J. Neurol., 250, 267-277.
39. Tarnopolsky, M.A.; Roy, B.D. and Donald, J.R. (1997) A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve, 20, 1502-1509. (Pubitemid 27512338)
40. Eleff, S.M.; Barker, P.B. and Blackband, S.J. (1990) Phosphorus magnetic resonance spectroscopy of patients with mitochondrial cytopathies demonstrates decreased levels of brain phosphocreatine Ann. Neurol., 27(6), 626-630.
41. Hagenfeldt, L.; von Dobeln, U.; Solders, G. and Kaijser, l. (1994) Creatine treatment in MELAS (letter). Muscle Nerve, 17, 1236-1237.
42. Komura, K.; Hobbiebrunken, E.; Wilichowski, E.K. and Hanefeld, F.A. (2003) Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr. Neurol., 28(1), 53-58.
43. Barisic, N.; Bernert, G.; Gruber, S.; Prayer, D.; Moser, E.; Bittner, R.E. and Stockler-Ipsiroglu, S. (2002) Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. Neuropediatrics, 33(3), 157-161.
44. Calvani, M.; Koverech, A. and Caruso, G. (1993) Treatment of mitochondrial diseases. In (DiMauro, S. and Wallace, D.C., Eds.). Mitochondrial DNA in human pathology. Raven Press: New York, pp. 173-198.
45. Kuroda, Y.; Ito, M.; Naito, E.; Yokota, I.; Matsuda, J.; Saijo, T.; Kondo, S.; Yoneda, Y.; Miyazaki, M.; Mori, K. and Iwamoto, H. (1997) Concomitant administration of sodium dichloroacetate and vitamin B1 for lactic acidemia in children with MELAS syndrome. J. Pediatr., 131(3), 450-452.
46. Koga, Y.; Ishibashi, M.; Ueki, I.; Yatsuga, S.; Fukiyama, R.; Akita, Y. and Matsuishi, T. (2002) Effects of L-arginine on the acute phase of stroke in three patients with MELAS. Neurology, 58(5), 827-828. (Pubitemid 34211569)
47. Rodriguez, M.C.; Macdonald, J.R.; Mahoney, D.J.; Parise, G.; Beal, M.F. and Tarnopolsky, M.A. (2006) Beneficial effects of creatine, CoQ(10), and lipoic acid in mitochondrial disorders. Muscle Nerve, 35(2), 235-242.
48. Komura, K.; Nakano, K.; Ishigaki, K.; Tarashima, M.; Nakayama, T.; Sasaki, K.; Saito, K. and Osawa, M. (2006) Creatine monohydrate therapy in a Leigh syndrome patient with A8344G mutation. Pediatr. Int., 48(4), 409-412. (Pubitemid 44127894)
49. Klopstock, T.; Querner, V.; Schmidt, F.; Gekeler, F.; Walter, M.; Hartard, M.; Henning, M.; Gasser, T.; Pongratz, D.; Straube, A.; Dieterich, M. and Muller-Felber, W. (2000) A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology, 55(11), 1748-1751.
50. Kornblum, C.; Schroder, R.; Muller, K.; Vorgerd, M.; Eggers, J.; Bogdanow, P.A.; Fabian, K.; Klockgether, T. and Zange, J. (2005) Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo- controlled, double-blind 31P-MRS crossover. Eur. J. Neurol., 12(4), 300-309. (Pubitemid 40477138)
51. Kemp, G.J.; Taylor, D.J.; Dunn, J.F.; Frostick, S.P. and Radda, G.K. (1993) Cellular energetics of dystrophic muscle. J. Neurol Sci., 116, 201-206.
52. 2+ handling and survival in mdx skeletal muscle cells. FEBS Lett., 439, 357-362.
53. De Luca, A.; Pierno, S.; Liantonio, A.; Cetrone, M.; Camerino, C.; Fraysse, B.; Mirabella, M.; Servidei, S.; Rüegg, U.T. and Conte Camerino, D.J. (2003) Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. Pharmacol. Exp. Ther., 304(1), 453-463.
54. Passaquin, A.C.; Renard, M.; Kay, L.; Challet, C.; Mokhtarian, A.; Wallimann, T. and Ruegg, U.T. (2002) Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul. Disord., 12(2), 174-182. (Pubitemid 33152736)
55. Granchelli, J.A.; Pollina, C. and Hudecki, M.S. (2000) Pre-clinical screening of drugs using the mdx mouse. Neuromuscul. Disord., 10(4-5), 235-239. (Pubitemid 30320912)
56. Felber, S.; Skladal, D.; Wyss, M.; Kremser, C.; Koller, A. and Sperl, W. (2000) Oral creatine supplementation in Duchenne muscular dystrophy: a clinical and 31P magnetic resonance spectroscopy study. Neurol. Res., 22(2), 145-150. (Pubitemid 30180791)
57. Tarnopolsky, M.A.; Mahoney, D.J.; Vajsar, J.; Rodriguez, C.; Doherty, T.J.; Roy, B.D. and Biggar, D. (2004) Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology, 62(10), 1771-1777.
58. Escolar, D.M.; Buyse, G.; Henricson, E.; Leshner, R.; Florence, J.; Mayhew, J.; Tesi-Rocha, C.; Gorni, K.; Pasquali, L.; Patel, K.M.; McCarter, R.; Huang, J.; Mayhew, T.; Bertorini, T.; Carlo, J.; Connolly, A.M.; Clemens, P.R.; Goemans, N.; Iannaccone, S.T.; Igarashi, M.; Nevo, Y.; Pestronk, A.; Subramony, S.H.; Vedanarayanan, V.V. and Wessel, H. (2005) CINRG randomized controlled trial of creatine and glutamine in duchenne muscular dystrophy. Ann. Neurol., 58(1), 151-155. (Pubitemid 40962472)
59. Pearlman, J.P. and Fielding, R.A. (2006) Creatine monohydrate as a therapeutic aid in muscular dystrophy. Nutr. Rev., 64(2), 80-88. (Pubitemid 43295035)
60. Kley, R.A.; Vorgerd, M. and Tarnopolsky, M.A. (2007) Creatine for treating muscle disorders. Cochrane Database Syst. Rev., 24(1), CD004760.
61. Radley, H.G.; De Luca, A.; Lynch, G.S. and Grounds, M.D. (2007) Duchenne muscular dystrophy: Focus on pharmaceutical and nutritional interventions Int. J. Biochem. Cell Biol., 39(3), 469-477.
62. Payne, E.T.; Yasuda, N.; Bourgeois, J.M.; Devries, M.C.; Rodriguez, M.C.; Yousuf, J. and Tarnopolsky, M.A. (2006) Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve, 33(1), 66-77. (Pubitemid 43062988)
63. Vorgerd, M.; Grehl, T.; Jager, M.; Muller, K.; Freitag, G.; Patzold, T.; Bruns, N.; Fabian, K.; Tegenthoff, M.; Mortier, W.; Luttmann, A.; Zange, J. and Malin, J.P. (2000) Creatine therapy in myophosphorylase deficiency (McArdle disease) a placebo-controlled crossover trial. Arch. Neurol., 57, 956-963.
64. Morton, A.J.; Hunt, M.J.; Hodges, A.K.; Lewis, P.D.; Redfern, A.J.; Dunnett, S.B. and Jones, L. (2005) A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. Eur. J. Neurosci., 21(4), 855-870.
65. Hersch, S.M.; Gevorkian, S.; Marder, K.; Moskowitz, C.; Feigin, A.; Cox, M.; Como, P.; Zimmerman, C.; Lin, M.; Zhang, L.; Ulug, A.M.; Beal, M.F.; Matson, W.; Bogdanov, M.; Ebbel, E.; Zaleta, A.; Kaneko, Y.; Jenkins, B.; Hevelone, N.; Zhang, H.; Yu, H.; Schoenfeld, D.; Ferrante, R. and Rosas, H.D. (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology, 66(2), 250-252.
66. Bender, A.; Auer, D.P.; Merl, T.; Reilmann, R.; Saemann, P.; Yassouridis, A.; Bender, J.; Weindl, A.; Dose, M.; Gasser, T. and Klopstock, T. (2005) Creatine supplementation lowers brain glutamate levels in Huntington's disease. J. Neurol., 252(1), 36-41. (Pubitemid 40179016)
67. Verbessem, P.; Lemiere, J.; Eijnde, B.O.; Swinnen, S.; Vanhees, L.; Van Leemputte, M.; Hespel, P. and Dom, R. (2003) Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology, 61(7), 925-930. (Pubitemid 37248646)
68. Sullivan, P.G.; Geiger, J.D.; Mattson, M.P. and Scheff, S.W. (2000) Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol., 48(5), 723-729. (Pubitemid 30823222)
69. Valenzuela, M.J.; Jones, M.; Wen, W.; Rae, C.; Graham, S.; Shnier, R. and Sachdev, P. (2003) Memory training alters hippocampal neurochemistry in healthy elderly. Neuroreport, 14(10),1333-1337.
70. Watanabe, A.; Kato, N. and Kato, T. (2002) Effects of creatine on mental fatigue and cerebral hemoglobin oxygenation. Neurosci. Res., 42, 279-285. (Pubitemid 34414988)
71. Rae, C.; Digney, L.A.; McEwan, R.S. and Bates, C.T. (2003) Oral creatine monohydrate supplementation improves brain performance: a double-blind,placebo- controlled, cross-over trial. Proc. R Soc. Lond. B, 270, 2147-2150.
72. Ferrier, C.H.; Alarcon, G.; Glover, A.; Koutroumanidis, M.; Morris, R.G.; Simmons, A.; Elwes, R.D.; Cox, T.; Binnie, C.D. and Polkey, C.E. (2001) NAA and creatine levels measured by 1H MRS relate to recognition memory. Neurology, 55, 1874-1883.